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Loss of PTEN Expression by Dermal Fibroblasts
Causes Skin Fibrosis
Sunil K. Parapuram1,5, Xu Shi-wen2,5, Christopher Elliott1, Ian D. Welch3, Helen Jones2, Murray Baron4,
Christopher P. Denton2, David J. Abraham2,6 and Andrew Leask1,6
Fibrosis represents a common pathway leading to organ failure and death in many diseases and has no effective
therapy. Dysregulated repair and excessive tissue scarring provides a unifying mechanism for pathological
fibrosis. The protein phosphatase and tensin homolog (PTEN) acts to dephosphorylate proteins, which
promotes tissue repair and thus could be a key fibrogenic mediator. To test this hypothesis, we first showed that
PTEN expression was reduced in skin fibroblasts from patients with the fibrotic autoimmune disease diffuse
systemic sclerosis (dSSc). To evaluate whether this deficiency could be sufficient for fibrogenesis in vivo, we
deleted PTEN in adult mouse fibroblasts. Compared with littermate control mice, loss of PTEN resulted in a
3-fold increase in dermal thickness due to excess deposition of collagen. PTEN-deleted fibroblasts showed
elevated Akt phosphorylation and increased expression of connective tissue growth factor (CTGF/CCN2).
Selective inhibition of the phosphatidylinositol 3-kinase/Akt pathway reduced the overexpression of collagen
and CCN2 by PTEN-deficient fibroblasts. Overexpression of PTEN reduced the overexpression of type I collagen
and CCN2 by dSSc fibroblasts. Thus, PTEN appears to be a potential in vivo master regulator of fibrogenesis;
PTEN agonists may represent anti-fibrotic treatments.
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INTRODUCTION
Fibrosis is associated with several disorders, including
systemic sclerosis (SSc), arthritis, nephropathy, liver cirrhosis,
and cancer, and is characterized by excess deposition of
collagen by activated connective tissue fibroblast cells and
their contraction, resulting in destruction of normal tissue
architecture/organ failure. There is no effective therapy for
fibrotic diseases, in part, because the underlying mechanisms
are poorly understood (Abraham et al., 2009). Different
cytokines (e.g., transforming growth factor-b (TGFb), platelet-
derived growth factor, and endothelin-1) act in concert to
promote fibrosis, and thus compounds targeting individual
cytokines may not be effective (Leask, 2010). Moreover,
different cytokines may be responsible for the fibrosis seen
in individual patients, making a ‘‘one-size-fits-all’’ approach
potentially problematic. Studies using fibroblasts from
patients with the fibrotic autoimmune disease SSc have
demonstrated that inhibition of individual cytokines results in
partial alleviation of persistent fibrotic phenotype, but
individual cytokines appear to be responsible for comple-
mentary, yet overlapping, aspects of the phenotype of these
cells (Chen et al., 2006; Ishida et al., 2006; Shi-Wen et al.,
2006; Leask, 2010, 2011). Indeed, clinical trials aimed at
exploiting these strategies have been disappointing (Leask,
2011). An alternative anti-fibrotic strategy might be to attack
proteins that are dysregulated within the actual target cells
(i.e., the fibroblasts) responsible for the excessive collagen
deposition characterizing scar tissue (Leask, 2011).
A plausible model for fibrosis is that there is excessive and/
or persistent activation of a tissue repair program. One
possible cause of this could be that proteins, which normally
suppress this process, are defective in fibrosis. One such
protein may be the phosphatase and tensin homolog (PTEN;
Tsugawa et al., 2002). The main substrate of PTEN, a dual
protein/lipid phosphatase, is phosphatidyl-inositol,3,4,5
triphosphate, which activates Akt. PI3K–Akt signaling has
been implicated in collagen production and proliferation in
lung fibroblasts (Lu et al., 2010). Akt has been shown to be
elevated in activity in SSc skin fibroblasts and mediates the
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ability of endothelin-1 to elevate myofibroblast activity in SSc
fibroblasts (Shi-wen et al., 2004; Jun et al., 2005) and
elevated Akt activity contributes to fibrogenic gene expres-
sion in SSc fibroblasts (Shi-wen et al., 2009). However,
whether dysregulation of the PTEN/Akt pathway is a hallmark
of SSc and is responsible for the persistent fibrotic phenotype
of SSc fibroblasts is unclear. Moreover, whether loss of PTEN
expression is sufficient for a fibrotic phenotype in vivo is
not known.
In this report, we investigate the contribution of PTEN to
the sclerosis observed in diffuse cutaneous SSc (dcSSc) by
examining the expression of PTEN in normal and dcSSc skin
fibroblasts and the effect of loss of PTEN expression in vivo
using a conditional knockout strategy (Zheng et al., 2002; Cai
et al., 2008; Liu et al., 2008, 2009). Our results show
valuable insights into the molecular mechanism underlying
fibrosis and suggest that reduced PTEN expression by dSSc
fibroblasts may be responsible for dermal fibrosis seen in SSc
patients.
RESULTS
PTEN protein expression is reduced in dcSSc dermal fibroblasts
We subjected dcSSc dermal fibroblasts isolated from explant
culture to western blot analyses using an anti-PTEN antibody.
Dermal fibroblasts from six healthy individuals and six
individuals with dcSSc (lesional) were used. PTEN protein
expression was significantly reduced in dcSSc fibroblasts
compared to normal, healthy fibroblasts (SScF vs. normal
fibroblasts in five out of six samples; Figure 1). Similarly,
phosphorylation of Akt was elevated in SScF (Figure 1).
Loss of PTEN expression by fibroblasts is sufficient for
fibrogenesis in vivo
As we observed reduced PTEN expression in dcSSc fibro-
blasts, we investigated whether loss of PTEN expression by
fibroblasts resulted in fibrosis in vivo. We used a strategy well
established in our laboratories to specifically delete target
genes in fibroblasts of mice (Zheng et al., 2002; Cai et al.,
2008; Liu et al., 2008, 2009). Briefly, mice with Pten gene
flanked by loxP sites (Groszer et al., 2001) were crossed with
mice expressing tamoxifen-dependent Cre recombinase
under the control of fibroblast-specific collagen 1a2 promo-
ter/enhancer (Zheng et al., 2002). Mice homozygous for
loxP–Pten allele and hemizygous for tamoxifen-dependent
collagen 1a2 promoter/enhancer-controlled Cre recombinase
were generated. Administration of tamoxifen to these mice
allowed conditional deletion of the Pten gene (K/K) in
fibroblasts. Genetically identical littermates or littermates
that did not have the Cre allele were administered corn oil
(vehicle) or tamoxifen, respectively, and served as control
mice (C/C). PCR analysis of DNA obtained from biopsies of
the ear showed that Pten gene was deleted only in animals
in which tamoxifen-activated Cre enzyme was present
(Figure 2a, lanes 5 and 6). Deletion of the PTEN gene was
further verified by immunohistochemical analysis of skin
(Figure 2b) and by subjecting dermal fibroblasts isolated from
these mice to indirect immunofluorescence analysis with an
anti-PTEN antibody (Figure 2c).
By 42 days post-cessation of tamoxifen injection, PTEN-
deficient mice, compared with their wild-type counterparts,
showed aB1.5-fold increase in dermal thickness (Figure 3a),
as revealed by hematoxylin and eosin staining, paralleled by
elevated collagen production, as visualized by Trichrome
stain (Figure 3b, Trichrome). Increase in collagen was further
validated by assessing hydroxyproline levels (Figure 3b,
hydroxyproline). Moreover, within the dermis, PTEN-defi-
cient animals possessed elevated expression of the fibrogenic
marker CCN2 (Leask et al., 2009) (Figure 3c). Also, fibrotic
lesions are characterized by the presence of a-smooth muscle
actin (a-SMA)-expressing myofibroblasts (Chen et al., 2005;
Abraham et al., 2009); loss of PTEN resulted in an increase in
a-SMA-positive cells (Figure 3d). Finally, fibrosis is a
fibroproliferative condition (Abraham et al., 2009); loss of
PTEN resulted in an increase in proliferating-cell nuclear
antigen-positive cells (Figure 3e). Collectively, these data
suggest that loss of PTEN expression by fibroblasts is sufficient
to result in fibrogenesis.
PTEN-deficient fibroblasts show overexpression of type I
collagen and CCN2 in an Akt/PI3-kinase-dependent fashion
To understand the mechanism by which loss of PTEN induces
a fibrotic phenotype, we first assessed the phosphorylation
status of Akt, a known target of PTEN (Carnero, 2010), and
found a significant increase in the number of dermal
fibroblasts expressing p-Akt in PTEN K/K mice compared
with controls (Figure 4a). These data were further verified by
western blot analysis of protein extracted from dermal
fibroblasts isolated from PTEN K/K and C/C mice.
PTEN-deficient fibroblasts showed elevated Akt phosphoryla-
tion and increased expression of type I collagen and CCN2
(Figure 4b).
To assess whether the Akt/PI3 kinase pathway was
responsible for this overexpression of type I collagen
and CCN2, control and PTEN-deficient cells were treated
overnight with wortmannin (100 nM) or LY294002 (10 mM).
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Figure 1. Scleroderma fibroblasts show reduced PTEN expression and
elevated Akt phosphorylation. Dermal fibroblasts from six normal individuals
(NF) and six individuals with SSc (SScF) were cultured. Equal amounts of
protein extracts were subjected to SDS–PAGE and western blot analysis with
anti-protein phosphatase and tensin homolog (PTEN), anti-phospho-Akt,
anti-Akt, and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibodies. Statistical analysis using a Student’s t-test shows that there is a
statistical significance (Po0.05) between PTEN expression and phospho-Akt
levels in SSc and control fibroblasts.
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Both wortmannin and LY294002 reduced the overexpression
of type I collagen and CCN2 by PTEN-deficient cells,
indicating the involvement of the PI3K–Akt pathway
in inducing the fibrotic phenotype in PTEN K/K mice
(Figure 4c). Treatment of cells with the ALK5 inhibitor
SB431542 (10 mM) did not reverse the overexpression of
CCN2 or type I collagen in PTEN-deficient cells (Figure 4d).
(It is interesting to note, however, that the ALK5 inhibitor
reduced basal expression of type I collagen in wild-type cells,
consistent with previous observations that ALK5 inhibition
reduced basal expression of type I collagen in normal, human
dermal fibroblasts (Chen et al., 2005)).
PTEN overexpression results in the rescue of the type I collagen
and CCN2 overexpression phenotype of dSSc fibroblasts
On the basis of these data, we assessed whether adenoviral-
based overexpression of PTEN could reverse the persistent
fibrotic phenotype of dSSc dermal fibroblasts, which over-
express type I collagen and CCN2 compared with healthy
control fibroblasts (Shi-wen et al., 1997; Shi-wen et al.,
2000). We found that, compared to cells transfected with
control virus, cells transfected with adenovirus containing
PTEN expression vector resulted in the overexpression of
PTEN and the reduced expression type I collagen and CCN2
protein expression (Figure 5). Collectively, these results
indicate that reduced PTEN expression is sufficient for
fibrogenic responses in skin fibroblasts.
DISCUSSION
There is no treatment for fibrotic disease in general and in SSc
in particular largely because the underlying deficiency
causing fibrosis is unclear. Our results are consistent with
previous findings that PTEN expression is downregulated in
liver tissues in a rat model of hepatic fibrosis (Hao et al.,
2009) and a recent report that showed first that Akt levels are
heightened in a PTEN-dependent fashion in fibroblasts
isolated from idiopathic pulmonary fibrosis patients and
second that PTEN-deficient mice are more susceptible to
bleomycin-induced lung fibrosis (Xia et al., 2008). However,
whether loss of PTEN is sufficient for fibrogenesis and
whether PTEN overexpression rescues the fibrotic phenotype
of cells derived from SSc skin lesions has not, at least as far as
we are aware, been shown until now.
TGFb suppresses PTEN expression (Kato et al., 2009;
Trojanowska, 2009; Yang et al., 2009) in normal cells. It is
interesting that ALK5 inhibition did not affect the phenotype
of the PTEN-deficient cells. This result is consistent with the
previous observations that ALK5 inhibitors do not affect
CCN2 overexpression in SSc fibroblasts (Chen et al., 2006).
The data contained in our report therefore suggest that PTEN
expression in SSc fibroblasts is reduced in a fashion
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Figure 2. Generation of mice bearing a fibroblast-specific deletion of PTEN.
We generated mice homozygous for loxP–Pten allele and hemizygous for
tamoxifen-dependent Cre expressed under the control of a fibroblast-specific
collagen 1a2 promoter/enhancer. Administration of tamoxifen deleted the
Pten gene only in mice in which tamoxifen-activated Cre enzyme was present.
(a) Deletion of Pten gene was tested by PCR genotyping of DNA extracted from
ear biopsies (lanes 1 and 2, corn-oil administration; lanes 3–6, tamoxifen
administration. (b) Loss of Pten was further verified by indirect
immunofluorescence analysis of skin tissue with an anti-protein phosphatase
and tensin homolog (PTEN) antibody. Whereas dermal fibroblasts of control
mice (C/C) showed immunostaining for PTEN protein, there was virtually no
stain for PTEN in the fibroblasts of mice deleted for PTEN (K/K). Bar¼100mM. (c)
Dermal fibroblasts isolated from PTEN C/C and K/K mice were also subjected
to indirect immunofluorescence with anti-PTEN antibody (red). Cells were
counterstained with 40,6-diamidino-2-phenylindole (blue) to detect nuclei.
Figure 3. Loss of PTEN expression in dermal fibroblasts results in increased skin thickness, collagen deposition, and CCN2 expression. Sections of paraffin
embedded skin tissue from protein phosphatase and tensin homolog (PTEN) C/C and K/K mice 42 days post-cessation of tamoxifen injection were examined.
(a) Hematoxylin and eosin (H and E) staining. Note increase in dermal thickness in PTEN-deficient mouse skin. (**Po0.001, N¼ 4). (b) Trichrome staining.
A representative of stained section is shown. Hydroxyproline analysis of skin further confirmed the increase of collagen in PTEN-deficient mice (*Po0.05,
N¼6). Indirect immunofluorescence analysis by (c) anti-CCN2 antibody was also performed. Note abundant CCN2-expressing cells in PTEN K/K mice as
opposed to control mice (C/C; **Po0.001, N¼ 4). (d) Anti-a-smooth muscle actin (SMA) antibody was also performed. Note abundant a-SMA-expressing cells
in PTEN K/K mice as opposed to control mice (C/C; **Po0.001, N¼ 4). (e) Anti-proliferating-cell nuclear antigen (PCNA) antibody was also performed. Note
abundant PCNA-expressing cells in PTEN K/K mice as opposed to control mice (C/C; **Po0.001, N¼ 4). Statistics were performed using the Student’s t-test.
Cells were counterstained with 40,6-diamidino-2-phenylindole (blue) to detect nuclei. Bar¼ 100mM.
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independent of canonical TGFb signaling. The data are
therefore consistent with the notion that SSc fibroblasts
possess a gene expression signature reminiscent of TGFb
signaling (Sargent et al., 2010), but are activated in a fashion
that is autonomous of canonical TGFb signaling but
dependent on non-canonical TGFb signaling pathways
(Trojanowska, 2009; Leask, 2011). One possible mechanism
underlying the reduced PTEN expression in SSc fibroblasts
could be due to reduced expression of peroxisome prolif-
erator-activated receptor-g; peroxisome proliferator-activated
receptor-g is reduced in SSc fibroblasts; and peroxisome
proliferator-activated receptor-g can regulate PTEN expres-
sion (Teresi and Waite, 2008; Wei et al., 2010).
Our data collectively suggest that PTEN normally
suppresses fibrogenesis in vivo and that loss of PTEN
expression is sufficient for fibrogenesis in vivo. Our data also
indicate that the reduction in PTEN expression in SSc
fibroblasts contributes to the persistent fibrotic phenotype
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Figure 4. Overexpression of type I collagen and CCN2 by PTEN-deficient fibroblasts depends on PI3K/Akt pathway. The mechanism by which loss of
protein phosphatase and tensin homolog (PTEN) induces a fibrotic phenotype was determined. Indirect immunofluorescence analysis indicates abundant
(a) p-Akt-positive in PTEN-deficient (K/K) mice compared with control mice (C/C; **Po0.001). Mice were examined 42 days post-cessation of tamoxifen
injection. Statistics were performed using the Student’s t-test. Bar¼100 mM. (b) Western blot analysis of protein extracts from dermal fibroblasts isolated
from PTEN K/K mice also showed increased expression of p-Akt compared with controls. Note that p-p38 and p-ERK were not affected by loss of PTEN.
(c) Cells were treated for 24 hours with DMSO (d), wortmannin (100 nM, Wo; a concentration shown to be specific/selective for Akt/PI3 kinase in cultured
cells; Arcaro and Wymann, 1993; Young et al., 1995; Shi-wen et al., 2004), and LY294002 (10mM, LY; a concentration shown to be specific/selective
for Akt/PI3 kinase in cultured cells; Sellers et al., 2000; Shi-wen et al., 2004) prior to protein extraction and western blot analysis. The increased expression
of collagen I, a-smooth muscle actin (SMA), and CCN2 in PTEN K/K dermal fibroblasts was reduced in the presence of wortmannin or LY294002
(*, decreased expression in the presence of inhibitor compared to DMSO control Po0.05; analysis of variance). (d) Cells were treated as in c, except
the ALK5 inhibitor SB431542 (10 mM; a concentration shown to be specific/selective for ALK 4/5/7 in cultured cells, Inman et al., 2002) was used
(*, decreased expression in the presence of inhibitor compared with DMSO control, Po0.05; analysis of variance). ERK, extracellular signal-regulated
kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCNA, proliferating-cell nuclear antigen; PI3K, phosphatidylinositol 3-kinase. Please note
that human dermal fibroblasts treated with a small interfering RNA directed toward PTEN resulted in increases in Col1a1 and CCN2 mRNA expression (see
Supplementary Figure S1 online).
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of these cells; PTEN agonists may be a therapeutic approach
to fibrotic diseases such as SSc. Moreover, PTEN knockout
mice could represent a new model for the fibrosis observed
in SSc.
MATERIALS AND METHODS
Patients and cell culture
Lesional fibroblasts were grown in Dulbecco’s modified Eagle’s
medium 10% fetal bovine serum (Invitrogen, Burlington, ON,
Canada) by explant culture from forearm skin of SSc patients with
diffuse cutaneous involvement (Leroy et al., 1988). The group of SSc
patients fulfilled the criteria of the American College of Rheumatol-
ogy for the diagnosis of SSc. The patients were female, and age-,
sex-, and site-matched fibroblasts from healthy individuals were also
used. Cells were used between passages 2 and 5 (Shi-wen et al.,
1997). All procedures were approved by the appropriate committee
at the University College London under written, informed patient
consent and adherence to the declaration of Helsinki Guidelines.
Dermal fibroblasts were isolated from PTEN-deficient and wild-type
control mice as previously described (Liu et al., 2008).
RNA analysis
Cells were lysed in Trizol (Invitrogen). RNA was prepared, quantified
spectrophotometrically, and subjected to real-time PCR analysis
using Assays-on-Demand primers and One-Step Master Mix as
previously described (Applied Biosystems, Foster City, CA; Pala
et al., 2008). Relative expression was assessed, compared with
glyceraldehyde-3-phosphate dehydrogenase mRNA, using the DD Ct
method. Samples were run in triplicate; expression values represent
averages (±SD) from different patients/mice.
Cell culture immunofluorescence and western analysis
Cells were lysed in 2% SDS, proteins quantified (Pierce, Nepean,
ON, Canada) and subjected to western blot analysis as previously
described with anti-PTEN (1:500, Cell Signaling, Danvers, MA),
anti-glyceraldehyde-3-phosphate dehydrogenase (1:5,000, Sigma,
St Louis, MO), anti-CCN2 (1:500, Abcam, Cambridge, MA), anti-
p-Akt, anti-Akt, anti-p-p38, anti-p-38, anti-p-ERK, anti-ERK (all
1:500, Cell Signaling), anti-a-SMA (1:1,000, Sigma), and anti-type I
collagen (1:1,000, Biodesign, Abingdon, UK) antibodies (Chen et al.,
2005). Cells were incubated for 24 hours in the presence or
absence of DMSO, wortmannin (100 nM; Arcaro and Wymann,
1993; Young et al., 1995; Shi-wen et al., 2004) or LY294002
(10 mM; Sellers et al., 2000; Shi-wen et al., 2004) or the ALK5
inhibitor SB431542 (10 mM; Inman et al., 2002; Sigma). Cells were
stained with anti-PTEN antibody and with a Texas Red-conjugated
secondary antibody (Jackson Laboratories, Bar Harbor, ME) prior
to subjecting cells to immunofluorescence microscopy (Zeiss,
North York, ON, Canada).
Animal studies
Mice with exon 5 of Pten gene flanked by loxP sites were
obtained from The Jackson Laboratory and mated with mice
expressing tamoxifen-dependent Cre recombinase under the control
of fibroblast-specific regulatory sequence from the pro-a2 (I)
collagen gene (Zheng et al., 2002). Mice homozygous for loxP–Pten
and hemizygous for Cre were administered tamoxifen (1mg per
mouse for 5 days) at 21–24 days of age to delete Pten gene,
specifically in fibroblasts. Deletion of PTEN was tested by PCR
genotyping. The deletion of floxed Pten allele was determined by
forward primer 50-ACTCAAGGCAGGGATGAGC-30 and two reverse
primers 50-AATCTAGGGCCTCTTGTGCC-30 and 50-gcttgatatc
gaattcctgcagc-30 (Lesche et al., 2002). Presence of Cre sequence
was determined using primers 50-ATCCGAAAAGAAAACGTT
GA-30 and 50-ATCCAGGTTACGGATATAGT-30 (Zheng et al.,
2002). To delete PTEN, 3-week-old mice were given intraperitoneal
injections of tamoxifen suspension (0.1ml of 10mgml1 4-hydro-
xytamoxifen, Sigma) over 5 days. Deletion of PTEN was tested
by PCR genotyping. Experiments were performed on littermate
mice homozygous for the loxP–PTEN allele (Jackson Laboratories)
and heterozygous for type I collagen Cre (Zheng et al., 2002)
that were treated with either tamoxifen (‘‘knockout PTEN’’, K/K) or
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Figure 5. Overexpression of PTEN results in reduced expression of type I collagen and CCN2 protein by scleroderma fibroblasts. Dermal fibroblasts
from three normal individuals (NF) and three individuals with SSc (SScF) were transfected with control adenovirus or adenovirus encoding protein
phosphatase and tensin homolog (PTEN). Cell extracts were then subjected to western blot analyses with anti-CCN2, anti-PTEN, anti-type I collagen,
and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies. Statistical significance (*Po0.05) was determined by analysis of variance.
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corn oil (‘‘control PTEN’’, C/C) alone. Mice were killed by CO2
euthanasia at time points indicated. Skin samples were collected
for histology, immunohistochemistry, hydroxyproline assay, and
for fibroblast cell culture. All animal protocols were given ethical
approval by the University of Western Ontario’s Animal Care
Committee.
Immunohistochemistry and assessment
Skin tissue sections (0.5 mm) were cut using a microtome
(Leica, Richmond Hill, ON, Canada) and collected on Superfrost
Plus slides (Fisher Scientific, Ottawa, ON, Canada). Sections were
then dewaxed in xylene and rehydrated by successive immersion in
descending concentrations of alcohol. When indicated, tissue was
stained with Harris’s hematoxylin and eosin. Skin thickness
measurements were assessed using image analysis software (North-
ern Eclipse, Empix, Missassagua, ON, Canada). To assess the effects
of PTEN deletion on collagen synthesis, Masson’s Trichrome
collagen stain was used. Sections were also subjected for immuno-
fluorescence staining. Tissue sections were blocked by incubation
with 5% BSA, 0.1% Triton X-100 in with phosphate-buffered saline
(overnight, 4 1C), washed with phosphate-buffered saline and then
incubated with primary antibodies for 1 hour at room temperature
under humidified conditions. Primary antibodies used were anti-
CCN2 (1:500 dilution, Abcam) and anti-p-Akt (1:50 dilution, Cell
Signaling). After primary antibody incubation, sections were then
washed with phosphate-buffered saline and incubated with appro-
priate fluorescent secondary antibodies (Invitrogen) 1 hour at 37 1C.
Sections were washed with phosphate-buffered saline, mounted
using 40,6-diamidino-2-phenylindole and photographed using a
Zeiss fluorescence microscope and Northern Eclipse software
(Empix). The percentage of positive cell staining was calculated by
numbers of cells per mm2 and was detected using image analysis
software (Northern Eclipse, Empix).
Hydroxyproline assay
Hydroxyproline assay was performed as a marker of collagen
synthesis in wound tissues as previously described (Samuel, 2009).
Tissues were homogenized in saline, hydrolyzed with 2 N NaOH for
30minutes at 120 1C. Briefly, skin biopsies were freeze-dried
overnight, dry-weight noted, followed by submersion in 6 M HCl
before being hydrolyzed at 110 1C for 18–24hours. The samples
were dessicated in the presence of NaOH overnight and then
reconstituted in 0.1 M HCl. Hydroxyproline levels were assessed by
modification of the Neumann and Logan’s reaction using Chlor-
amine T and Ehrlich’s reagent (Sigma) using a hydroxyproline
standard curve and measuring at 558 nm. Values were expressed as
mg of hydroxyproline per mg of protein.
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